Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative diseaseOKYO’s introduction to the broader ophthalmology community at ASCRS...
April 29, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

Robert J. Dempsey, MBA, Chief Executive Officer, to present at EyeceleratorRaj Patil, PhD, Chief Scientific Officer, to present at ARVO LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO...
April 07, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

LONDON and NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
March 19, 2026 12:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Chairman and Founder Acquires Shares

LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
March 19, 2026 10:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Director Acquires Shares

LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
March 19, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
March 18, 2026 07:00 ET | Source: OKYO Pharma LTD

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
February 23, 2026 11:00 ET | Source: OKYO Pharma LTD

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
February 12, 2026 22:20 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
February 12, 2026 16:01 ET | Source: OKYO Pharma LTD

OKYO Pharma Announces Public Offering of Ordinary Shares

LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...